Reference entry · Synthetic tripeptide bioregulator
Cartalax
Also known as: Ala-Glu-Asp · AED tripeptide bioregulator
- Class
- Synthetic tripeptide bioregulator
- Size
- 3 amino acids
- Primary targets (literature)
- Chondrocyte and cartilage-aging literature
- Regulatory context
- Not FDA-approved. Cartilage-oriented preclinical data do not establish joint or connective-tissue indications in humans.
Overview
Cartalax is an Ala-Glu-Asp tripeptide bioregulator discussed in cartilage and connective-tissue aging research. It shares sequence motifs with other Khavinson tetrapeptides but is a distinct catalog entity requiring explicit identity proof.
Mechanism in research literature
Literature describes chondrocyte proliferation and extracellular-matrix gene-expression changes in aging cartilage models — overlapping conceptually with recovery peptides but without their independent bibliographies.
Common research focus areas
- Chondrocyte culture and matrix marker assays
- Cartilage aging rodent models
- Sequence disambiguation vs. epithalon (AEDG)
- Tripeptide purity and salt-form specification
Full literature roundup
Read the cited research summary
An Ala-Glu-Asp tripeptide bioregulator discussed in cartilage and connective-tissue aging research. What the Khavinson literature reports — and how it differs from recovery peptides.
Cartalax research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.